Breast cancer-focused medical device startup Elucent Medical has raised $7.2 million in a Series A round of financing, according to an Xconomy report.
The funding round for the Eden Prairie, Minn.-based company closed late last year, according to Xconomy, who spoke to co-founder and CEO Laura King.
Elucent is developing a more sophisticated version of hook wire equipment for breast cancer procedures, which are currently used to mark areas which will be removed during surgeries. The company’s device would eliminate the need for a metal clip, which are often left in patients long term, and replace it with a small biocompatible device which emits a pulse that can be detected by a proprietary detector, also made by Elucent.
“The breast doesn’t have a lot of anatomical landmarks for the radiologist and the surgeon to actually be able to know or describe where the suspicious lesion is,” King told Xconomy.
The advanced clip system could allow for better visualization, with surgeons able to get a 3-dimensional image of where it is located and where tissue was removed. The system could also eliminate the need for the secondary hook-wire procedure, as the biocompatible hook itself would be placed after tissue was removed initially, according to the report.
“The patient can avoid a second painful and invasive procedure,” King told Xconomy.
Elucent plans to seek FDA 510(k) clearance initially, but does not have a target date for application currently, according to the report.
Funding in the round was led by Venture Investors and Baird Capital, according to Xconomy, with funds slated to support further product development.